Core benefits for pharmaceutical development
1. Boosting solubility and bioavailability
HPBCD and SBECD form reversible host–guest complexes with hydrophobic APIs. These inclusion complexes increase aqueous solubility and dissolution rate, which can lead to improved membrane permeability and enhanced systemic exposure for oral and parenteral products. SBECD's charged substituents often provide superior solubilization for high-demand injectable systems.
2. Protecting sensitive APIs and extending stability
Encapsulation within the cyclodextrin cavity reduces APIs' exposure to degradative influences such as light, oxygen and moisture. HPBCD works especially well for moisture-sensitive solids and solid dispersions, while SBECD is highly effective in liquid and sterile formulations where rapid solubilization and stability are required.
3. Reducing irritation and improving safety profiles
By limiting direct drug–tissue contact, cyclodextrin inclusion can decrease local irritation and lower the incidence of certain side effects. This effect is valuable in formulations for oral (taste masking), nasal, ophthalmic and injectable applications.
4. Enabling flexible dosage forms
Cyclodextrin complexes can convert liquids or volatile actives into stable, free-flowing powders. This enables development of instant-dissolve powders, orally disintegrating tablets, sterile dry powders for reconstitution, and other modern dosage formats. HPBCD is commonly used in solid dosage development, while SBECD is preferred for high-solubility liquid and parenteral systems.
5. Supporting advanced delivery strategies and analysis
Beyond solubilization, cyclodextrins act as functional building blocks for controlled-release matrices, molecular-recognition assemblies, and BBB-penetration strategies. Their stereoselectivity also makes them useful in chiral separations and analytical method development.
Manufacturing & quality strengths — Xi'an DELI
Xi'an DELI brings 26 years of manufacturing experience in cyclodextrin derivatives. Our core capabilities include:
- Production scale and stability — consistent batch output of 2–3 tons per run
- Stringent quality control: comprehensive CoA, ICP, residual solvents and microbiology testing
- Technical support for formulation screening and sample evaluation
- Supply to pharmaceutical, veterinary and chemical markets with global logistics support
We provide CoA, SDS, and small evaluation samples to support formulation work and regulatory submissions.
Closing remarks
HPBCD and SBECD remain essential excipients for tackling classic formulation obstacles and enabling new drug-delivery concepts. With proven manufacturing experience and formulation support, Xi'an DELI continues to partner with developers to translate cyclodextrin science into viable pharmaceutical products.